famotidine has been researched along with Cancer of Pancreas in 2 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altschul, M | 1 |
| Simpson, KW | 1 |
| Dykes, NL | 1 |
| Mauldin, EA | 1 |
| Reubi, JC | 1 |
| Cummings, JF | 1 |
| Pisegna, JR | 1 |
| Norton, JA | 1 |
| Slimak, GG | 1 |
| Metz, DC | 1 |
| Maton, PN | 1 |
| Gardner, JD | 1 |
| Jensen, RT | 1 |
1 trial available for famotidine and Cancer of Pancreas
| Article | Year |
|---|---|
Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.
Topics: Adult; Aged; Cimetidine; Dose-Response Relationship, Drug; Duodenal Neoplasms; Famotidine; Female; F | 1992 |
1 other study available for famotidine and Cancer of Pancreas
| Article | Year |
|---|---|
Evaluation of somatostatin analogues for the detection and treatment of gastrinoma in a dog.
Topics: Animals; Anti-Ulcer Agents; Antineoplastic Agents, Hormonal; Dog Diseases; Dogs; Dose-Response Relat | 1997 |